Publications

Export 9078 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Z
Zaafan, M. A., H. F. Zaki, A. I. El-Brairy, and S. A. Kenawy, "Pyrrolidinedithiocarbamate attenuates bleomycin-induced pulmonary fibrosis in rats: Modulation of oxidative stress, fibrosis, and inflammatory parameters.", Experimental lung research, vol. 42, issue 8-10, pp. 408-416, 2016. Abstract

OBJECTIVE: The current study aimed to investigate the modulatory effects of pyrrolidinedithiocarbamate (PDTC; 100 mg/kg) on bleomycin-induced pulmonary fibrosis (5 mg/kg; intratracheal) in rats.

MATERIALS AND METHODS: Rats were randomly assigned to three groups: normal control, bleomycin control, and PDTC-treated groups. Lung injury was evaluated through histological examination, immunohistochemical detection of inducible nitric oxide synthase (iNOS) in lung tissue and evaluating the total and differential leucocytes count in bronchoalveolar lavage fluid. Lung tissue was used for biochemical assessment of lung content of hydroxyproline, transforming growth factor beta-1 (TGF-β1), tumor necrosis factor-alpha (TNF-α) as well as analysis of lipid peroxides, reduced glutathione (GSH), and total nitrite contents.

RESULTS: PDTC attenuated bleomycin-induced pulmonary fibrosis as evidenced by histological observations, decreased iNOS expression and prevention of bleomycin-induced altered total and differential leukocytes count. Additionally, PDTC caused a significant decrease in lung contents of hydroxyproline, TGF-β1, TNF-α, lipid peroxides, and total nitrite coupled with increase in lung GSH content as compared to bleomycin control group.

CONCLUSION: PDTC attenuated bleomycin-induced pulmonary fibrosis in rats via its anti-inflammatory, antioxidant, and antifibrotic activities.

Zaafar, D., H. M. A. Khalil, R. Elnaggar, D. Z. Saad, and R. A. Rasheed, "Protective role of hesperetin in sorafenib-induced hepato- and neurotoxicity in mice via modulating apoptotic pathways and mitochondrial reprogramming.", Life sciences, vol. 336, pp. 122295, 2024. Abstract

INTRODUCTION: Sorafenib, an FDA-approved standard chemotherapy for advanced hepatocellular carcinoma, is associated with numerous adverse effects that significantly impact patients' physiological well-being. Consequently, identifying agents that mitigate these side effects while enhancing efficacy is crucial. Hesperetin, a flavone present in fruits and vegetables, possesses antioxidant, anti-inflammatory, and anti-cancer properties. This study aimed to investigate the hepatotoxic and neurotoxic effects of sorafenib and the potential protective role of hesperetin.

MATERIALS AND METHODS: Swiss albino mice were orally administered sorafenib (100 mg/kg) alone or in combination with hesperetin (50 mg/kg) over 21 days. Behavioral assessments for anxiety and depressive-like behaviors were conducted. Additionally, evaluations encompassed apoptotic activity, mitochondrial integrity, liver enzyme levels, proliferation rates, and histopathological changes.

RESULTS: Combining hesperetin with sorafenib showed improvements in behavioral alterations, liver damage, brain mitochondrial dysfunction, and liver apoptosis compared to the sorafenib-only group in mice.

CONCLUSION: Hesperetin exhibits potential as an adjunct to sorafenib, mitigating its side effects by attenuating its toxicity, enhancing efficacy, and potentially reducing the occurrence of sorafenib-induced resistance through the downregulation of hepatocyte growth factor levels.

Zaafar, D., H. M. A. Khalil, G. E. Elkhouly, A. S. Sedeky, Y. H. Ahmed, M. G. Khalil, and Y. Abo-Zeid, "Preparation and characterization of Sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study.", Drug delivery and translational research, 2024. Abstract

Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related deaths worldwide. Current treatment strategies include surgical resection, liver transplantation, liver-directed therapy, and systemic therapy. Sorafenib (Sor) is the first systemic drug authorized by the US Food and Drug Administration (FDA) for HCC treatment. Nevertheless, the conventional oral administration of Sor presents several limitations: poor solubility, low bioavailability, drug resistance development, and off-target tissue accumulation, leading to numerous adverse effects. Nano-emulsion, a nano-delivery system, is a viable carrier for poorly water-soluble drugs. It aims to enhance drug bioavailability, target organ accumulation, and reduce off-target tissue exposure, thus improving therapeutic outcomes while minimizing side effects. This study formulated Sor nano-emulsion (Sor NanoEm) using the homogenization technique. The resultant nano-emulsion was characterized by particle size (121.75 ± 12 nm), polydispersity index (PDI; 0.310), zeta potential (-12.33 ± 1.34 mV), viscosity (34,776 ± 3276 CPs), and pH (4.38 ± 0.3). Transmission Electron Microscopy exhibited spherical nano-droplets with no aggregation signs indicating stability. Furthermore, the encapsulation of Sor within the nano-emulsion sustained its release, potentially reducing the frequency of therapeutic doses. Cytotoxicity assessments on the HepG2 cell line revealed that Sor NanoEm had a significantly (P < 0.05) more potent cytotoxic effect compared to Sor suspension. Subsequent tests highlighted superior pharmacokinetic parameters and reduced dosage requirements of Sor NanoEm in mice. It exhibited an enhanced safety profile, particularly in behavior, brain, and liver, compared to its suspended form. These findings underscore the enhanced pharmacological and toxicological attributes of Sor Nano-emulsion, suggesting its potential utility in HCC treatment.

Zaater, A., and M. REFAAT, "Prognosis of cervical degenerative myelopathy after multilevel anterior cervical discectomies and fusion", Egyptian journal of neurosurgery , vol. 29, issue 1, pp. 57-62, 2014.
Zaazaa, A., I. Fathy, O. Ayman, A. Hassanin, and H. Ghanem, "A pilot study of penile hemodynamics in men with penile curvatures", International Journal of Impotence Research, vol. 29, pp. 86-88, 2017. hemodynamics_of_pc_published.pdf
Zaazaa, A. A., I. Fathy, O. Ayman, A. Hassanin, and H. Ghanem, "A pilot study of penile hemodynamics in men with penile curvatures.", International journal of impotence research, vol. 29, issue 2, pp. 86-88, 2017 Mar. Abstract

Penile curvature (PC) is bothersome to the patient. PC is either congenital or acquired. In most of the circulatory system, blood flows in a laminar profile with minimal energy expenditure. When a fluid passes in a curved tube, the laminar profile is disturbed and changed into a turbulent flow. It increases the energy expenditure and reduces the flow. Turbulent flow may have a role in the development of an atherosclerotic plaque and in localizing its site. The aim of this research was to study penile hemodynamics before and after correction of PC. This prospective study included 20 participants, with PC more than 30°. For each participant, preoperative color duplex doppler ultrasonography (CDDU), correction of the curvature using 16 dot plication technique and post-operative CDDU were done. Furhtermore, arterial systolic velocity was estimated distal to the site of curvature/correction every 5 min for 25 min. The degree of curvature ranged from 30° to 90° with a mean of 55±18.98. Comparative study between the preoperative and post-operative data proved a significantly higher postoperative peak systolic velocity distal to the site of correction, whereas CDDU data had insignificant differences. We concluded that correction of PC is associated with improvement of penile arterial blood flow distal to the site of correction.

Zacharakis, E., G. Garaffa, A. A. Raheem, A. N. Christopher, A. Muneer, and D. J. Ralph, "Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation.", BJU international, vol. 114, issue 4, pp. 576-81, 2014 Oct. Abstract

OBJECTIVE: To compare the long-term results of early and delayed insertion of a penile prosthesis (PP) in men with refractory ischaemic priapism (IP).

PATIENTS AND METHODS: Early insertion of a PP was carried out in 68 men with IP within a median of 7 days from the onset of priapism, while 27 had delayed insertion after a median of 5 months. The results for sexual ability, satisfaction and subjective penile shortening were assessed by questioning at follow-up visits.

RESULTS: In the early group, a malleable and an inflatable PP were implanted in 64 and four patients, respectively. After a median follow-up of 17 months, six patients needed revision surgery due to infection and curvature. Patient's satisfaction rate and ability to have sexual intercourse was 96%. In the delayed group, a malleable PP was inserted in 12 patients and an inflatable in the remaining 15. In all, 80% of the patients required a second corporotomy and downsized cylinders due to dense fibrosis. After a median follow-up of 21 months,seven patients required revision surgery due to infection,erosion and mechanical failure. In all, 25 patients were able to engage in sexual intercourse but the satisfaction rate was only 60% mainly due to significant penile shortening.

CONCLUSIONS: Early PP implantation should be the preferred option inpatients with IP, as the procedure is technically easier, has less complication rates and allows greater preservation of penile length.

Zaghla, H., N. Sameer, H. Akabawy, and A. fahmy, "The prognostic effect of statin therapy on endothelial function in patients with early sepsis", The medical journal of Cairo university, vol. 78, issue No 1, 2010.
Zaghlol, A., Z. Kandil, M. Yousif, R. S. E. Dine, and W. Elkady, "Phytochemical analysis of Euphorbia greenwayi aerial parts: antioxidant and anti-inflammatory potential", Egyptian Journal of Chemistry, vol. 67, issue 3: National Information and Documentation Centre (NIDOC), Academy of Scientific …, pp. 515-525, 2024. Abstract
n/a
Zaghlol, K., S. Sakran, M. El-Sharkawi, and A. Said, "Petrographical, structural, and remote sensing–based mapping of Gebel Atawi area, central Eastern Desert, Egypt", Arabian Journal of Geosciences, vol. 14, pp. Paper No. 1368, 2021.
Zaghloul, M. S., S. A. El-Badawi, and H. Abd Elbaky, "Professor Hassan K. Awwad; The Father of Radiation Oncology and Radiobiology in Egypt and the Arab World, His Good Deeds Last Forever and Inspire us for the Future.", Journal of the Egyptian National Cancer Institute, vol. 19, issue 1, pp. 1-2, 2007 Mar. Abstract

Our most respected professor Hassan K. Awwad passed away on January 5th, 2007, at the age of 81. He was considered as the father of radiotherapy in Egypt. He was always named "The Professor", as he was the founder of the radiotherapy departments at the National Cancer Institute, Cairo University&Faculty of Medicine, Alexandria University. He also shared in developing NEMROCK (Kasr El Aini Center of Radiation Oncology and Nuclear Medicine), the place where he graduated and worked during his early years of experience. He, together with professor Reda Hamza, dean of NCI, Cairo at that time, had initiated 7 oncology centers all over Egypt, from Aswan in the South to Dammietta and Damanhour in the North. These 7 centers were developed by the Ministry of Health. Prof. Awwad and Prof. Hamza were responsible for facility providing and plans. They chose all the necessary equipment, tools and personnel. These centers were in action since 1988 and are currently taking care of the oncology patients in a wide area of the country. Prof. Awwad graduated from the Faculty of medicine, Cairo University, in 1949. He had his Medical Doctorate (MD) in Radiotherapy from Alexandria University in 1956. The International Atomic Energy Agency (IAEA) awarded him fellowships in France (Institute Gustave Rossy) to gain experience in brachytherapy in 1956 and 1971, England 1956, 1959. Another fellowship was awarded to Prof Awwad in Harvard University (Peter Bent Brigham Hospital) in radiobiology and radiotherapy during the years 1964-1965. He personally and with other members of the National Cancer Institute gave much of their efforts and time to teach, train and guide young radiotherapists, biologists, physicists and radiation therapists through direct on-hand teaching and training as well as holding training courses for radiation oncologists, physicists and technologists. He insisted to ensure its regularity 4 times yearly. These courses trained a lot of personnel from all over Egypt, Sudan, Libya, Palastine, Iraq, Uganda, Nigeria and other countries. He himself had many teaching missions in different Arab countries (Saudi Arabia, Kuwait and others) for the sake of groups of his students that could not come to Egypt. He served as the head of the Department of Radiation Oncology for more than 15 years (1970-1985), full time Professor in Radiation Oncology and Radiobiology (1985-2007), Professor of Radiotherapy, Alexandria University (1954-1970), Chief of the Department of Nuclear Medicine, Medical Research Institute, University of Alexandria (1963-1964), Chief of the Radiotherapy Unit in the Heliopolis Hospital, Ministry of Public Health, 1985-2007. He was co-founder of the Egyptian Society of Cancer and acted as vice present and head of the scientific committee of the society. He shared the activities of many Egyptian, Arab and international scientific societies. His activities in these societies were great. Prof. Awwad had direct contact with his students that never ended, even after some of them left to work in other places in USA, Canada, Europe or Arab Countries. His students' specialty varied between radiobiology, pharmacology, biochemistry, tumor biology, radiation oncology, medical oncology and surgical oncology. Prof. Awwad had more than 100 published articles on hypoxia and hypoxic cell radiosensitizers, biology of growth of human tumors, biology and clinical models of the time factor in external beam radiotherapy, biology and mathematical models of time factor in brachytherapy, radioactive dynamic cancer studies of plasma protein metabolism, radioactive dynamic factor studies of blood disorders and lymphoma, radiation damage of DNA and normal tissues,head and neck cancer, bladder cancer, breast cancer, cervical cancer and development and optimization of clinical radiotherapy. He had continuous cooperation and collaboration with many of the great scientists and clinicians in Holland, France, United Kingdom, USA and Japan. He continued to exchange ideas with these great people all through his life and till the last moments of his extended fruitful life. Prof. Awwad wrote many books for a wide diversity of readers, for the lay people in Arabic, for radiographers, young oncologist, and the highly experienced radiation oncologists and radiobiologists. His book "Radiation Oncology: Radiobiological and Physiobiological Perspectives" was a real translation of radiobiology language to the oncologist and at the same time translation of the oncologist language to the biologist. This book ended with establishing a common language for both teams. In addition, it led other books in these specialties to communicate with the same language. The good news is that Prof. Awwad had completed the second edition of this book just before passing away. This second edition is really a totally new book coping with the advancement of knowledge reached till the end of 2006. We are sure that this book with all other good deeds performed by Prof. Awwad, will keep his memory in Egypt as well as elsewhere in the whole world.

Zaghloul, M. S., R. Boutrus, H. El-Hossieny, Y. AbdelKader, I. El-Attar, and M. Nazmy, "A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.", International journal of clinical oncology, vol. 15, issue 4, pp. 382-9, 2010. Abstract

BACKGROUND: Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer. The aim of this study was to evaluate the effect of zoledronic acid on SREs in patients with bone metastases from bladder cancer.

PATIENTS AND METHODS: Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months.

RESULTS: The patients (n = 40) were evenly distributed between the two treatment groups, and the baseline demographics of the two groups were similar. The follow-up varied from 8 to 65 weeks (median 24 weeks). Compared with patients receiving placebo, those receiving zoledronic acid had a lower mean incidence of SREs (2.05 +/- 1.0 vs. 0.95 +/- 0.9, respectively), and a larger proportion did not experience an on-study SRE (2 vs. 8 patients, respectively). Zoledronic acid also prolonged the median time to first SRE compared with the placebo (16 vs. 8 weeks, respectively). Multiple event analysis of SREs revealed that zoledronic acid decreased the risk of SRE development by 59% (hazard ratio 0.413). Zoledronic acid also increased the 1-year survival rate compared with placebo (36.3 +/- 11.2 vs. 0%, respectively). Zoledronic acid was generally well tolerated in our patient population.

CONCLUSIONS: Zoledronic acid therapy decreased the incidence of SREs and improved the 1-year survival rate of patients with bone metastases from bladder cancer, potentially through its anticancer activity.

saied zaghloul, H., "Prophylactic effect of Vitamin B- complex (B12, B6, B1) on Optic neurotoxicity of Metronidazole ", the 3rd Annual Conference of Forensic Medicine and Toxicology, Faculty of Medicine Cairo Unversity, March,1999.
d Zaghloul, M. S. a, M. a El Naggar, A. b El Deeb, H. c Khaled, and N. b Mokhtar, "Prognostic implication of apoptosis and angiogenesis in cervical uteri cancer", International Journal of Radiation Oncology Biology Physics, vol. 48, no. 5, pp. 1409-1415, 2000. AbstractWebsite

Purpose: A retrospective study was performed to investigate the relationship between spontaneous apoptosis and angiogenesis uterine cervix squamous cell carcinoma patients. The prognostic value of each (and both) of these biologic parameters was also tested.Methods and Materials: The pathologic materials of 40 cervical uteri squamous cell carcinoma patients were examined and immunohistochemically stained to determine the tumor angiogenesis (tumor microvascular score), using factor VIII-related antigen, and their tumor apoptotic index (AI), using the TdT-mediated dUTP nick end-labeling (TUNEL) method. Three patients were Stage I, 18 were Stage II, 15 were Stage III, and 4 were Stage IV (FIGO classification). All patients were treated with radical radiotherapy and all had follow-up for more than 2 years.Results: The mean AI was 15.1 ± 12.8, with a median of 8.3. The mean tumor microvascular score was 3 9.7 ± 14.4, with a median of 3 8. The patients' age and tumor grade did not seem to significantly affect the prognosis. On the other hand, AI and angiogenesis (tumor microvascular score) were of high prognostic significance. The 3-year disease-free survival (DFS) rate for the patients having AI above the median was 78% (confidence interval [CI] 69-87%), compared to 32% (CI 22-42%) for those having AI below the median. The DFS was 18% (CI 9-27%) for patients having an angiogenesis score above the median, while it was 86% (CI 78-94%) for those patients having a score below the median.Conclusion: Determination of both tumor microvascular score and AI can identify patients with the best prognosis of 100% DFS (with low angiogenesis score and high AI). Women with a high score and low AI had the worst prognosis (DFS = 3%, CI 1-5%). Moreover, high AI can compensate partially for the aggressive behavior of tumors showing a high rate of angiogenesis. Copyright (C) 2000 Elsevier Science Inc.

d Zaghloul, M. S. a, M. a El Naggar, A. b El Deeb, H. c Khaled, and N. b Mokhtar, "Prognostic implication of apoptosis and angiogenesis in cervical uteri cancer", International Journal of Radiation Oncology Biology Physics, vol. 48, no. 5, pp. 1409-1415, 2000. AbstractWebsite

Purpose: A retrospective study was performed to investigate the relationship between spontaneous apoptosis and angiogenesis uterine cervix squamous cell carcinoma patients. The prognostic value of each (and both) of these biologic parameters was also tested.Methods and Materials: The pathologic materials of 40 cervical uteri squamous cell carcinoma patients were examined and immunohistochemically stained to determine the tumor angiogenesis (tumor microvascular score), using factor VIII-related antigen, and their tumor apoptotic index (AI), using the TdT-mediated dUTP nick end-labeling (TUNEL) method. Three patients were Stage I, 18 were Stage II, 15 were Stage III, and 4 were Stage IV (FIGO classification). All patients were treated with radical radiotherapy and all had follow-up for more than 2 years.Results: The mean AI was 15.1 ± 12.8, with a median of 8.3. The mean tumor microvascular score was 3 9.7 ± 14.4, with a median of 3 8. The patients' age and tumor grade did not seem to significantly affect the prognosis. On the other hand, AI and angiogenesis (tumor microvascular score) were of high prognostic significance. The 3-year disease-free survival (DFS) rate for the patients having AI above the median was 78% (confidence interval [CI] 69-87%), compared to 32% (CI 22-42%) for those having AI below the median. The DFS was 18% (CI 9-27%) for patients having an angiogenesis score above the median, while it was 86% (CI 78-94%) for those patients having a score below the median.Conclusion: Determination of both tumor microvascular score and AI can identify patients with the best prognosis of 100% DFS (with low angiogenesis score and high AI). Women with a high score and low AI had the worst prognosis (DFS = 3%, CI 1-5%). Moreover, high AI can compensate partially for the aggressive behavior of tumors showing a high rate of angiogenesis. Copyright (C) 2000 Elsevier Science Inc.

Zaghloul, M. S., R. Boutrus, H. El-Hossieny, Y. AbdelKader, I. El-Attar, and M. Nazmy, "A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.", International journal of clinical oncology, vol. 15, issue 4, pp. 382-9, 2010. Abstract

BACKGROUND: Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer. The aim of this study was to evaluate the effect of zoledronic acid on SREs in patients with bone metastases from bladder cancer.

PATIENTS AND METHODS: Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months.

RESULTS: The patients (n = 40) were evenly distributed between the two treatment groups, and the baseline demographics of the two groups were similar. The follow-up varied from 8 to 65 weeks (median 24 weeks). Compared with patients receiving placebo, those receiving zoledronic acid had a lower mean incidence of SREs (2.05 +/- 1.0 vs. 0.95 +/- 0.9, respectively), and a larger proportion did not experience an on-study SRE (2 vs. 8 patients, respectively). Zoledronic acid also prolonged the median time to first SRE compared with the placebo (16 vs. 8 weeks, respectively). Multiple event analysis of SREs revealed that zoledronic acid decreased the risk of SRE development by 59% (hazard ratio 0.413). Zoledronic acid also increased the 1-year survival rate compared with placebo (36.3 +/- 11.2 vs. 0%, respectively). Zoledronic acid was generally well tolerated in our patient population.

CONCLUSIONS: Zoledronic acid therapy decreased the incidence of SREs and improved the 1-year survival rate of patients with bone metastases from bladder cancer, potentially through its anticancer activity.

Zaghloul, M. S., M. El Baradie, M. El Baradie, S. Abdel-Fatah, A. Taher, and M. Shalaan, "Prognostic index for primary adenocarcinoma of the urinary bladder.", The Gulf journal of oncology, issue 2, pp. 47-54, 2007. AbstractWebsite

AIM: To determine the working independent prognostic factors and the prognostic index of adenocarcinoma of the urinary bladder. The effect of adding postoperative radiotherapy to radical cystectomy on this prognostic index was also investigated.

PATIENTS AND METHODS: Two hundred and sixteen patients having adenocarcinoma of the urinary bladder were treated with radical cystectomy and pelvic lymphadenectomy with (82 patients) or without (134) postoperative radiotherapy. Postoperative radiotherapy (PORT) was given to the whole pelvis in a dose of 50 Gy/25 fractions over 5 weeks, and started 4-10 weeks after surgery.

RESULTS: The 5-year disease-free survival rate was 44 +/- 4% for the whole group. Postoperative radiotherapy improved the disease-free survival significantly from 33 +/- 6% for cystectomy alone Introduction to 58 +/- 6% for PORT patients (P = 0.002). The independent prognostic factors for DFS were the pathological stage, histological subtypes, nodal involvement and the addition of postoperative radiotherapy. The stratification of patients using prognostic indices according to the pathological findings produces identifiable prognostic groups. Postoperative radiotherapy improved the DFS significantly in the intermediate and high risk indices (p = 0.0004 and 0.0002 respectively).

CONCLUSIONS: The identified prognostic indices with their prognostic group could be used not only as a predictor of disease-free survival but also as a good predictor for the need to add adjuvant therapy in adenocarcinoma of the urinary bladder.

Zaghloul, M. S., R. Boutrus, H. El-Hossieny, Y. AbdelKader, I. El-Attar, and M. Nazmy, "A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.", International journal of clinical oncology, vol. 15, issue 4, pp. 382-9, 2010 Aug. Abstract

BACKGROUND: Zoledronic acid treatment reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from breast, lung, and urologic cancers including prostate and renal cancer. The aim of this study was to evaluate the effect of zoledronic acid on SREs in patients with bone metastases from bladder cancer.

PATIENTS AND METHODS: Patients with bone metastases from bladder cancer who were receiving palliative radiotherapy were randomized to placebo or zoledronic acid (4 mg intravenous monthly) for 6 months.

RESULTS: The patients (n = 40) were evenly distributed between the two treatment groups, and the baseline demographics of the two groups were similar. The follow-up varied from 8 to 65 weeks (median 24 weeks). Compared with patients receiving placebo, those receiving zoledronic acid had a lower mean incidence of SREs (2.05 +/- 1.0 vs. 0.95 +/- 0.9, respectively), and a larger proportion did not experience an on-study SRE (2 vs. 8 patients, respectively). Zoledronic acid also prolonged the median time to first SRE compared with the placebo (16 vs. 8 weeks, respectively). Multiple event analysis of SREs revealed that zoledronic acid decreased the risk of SRE development by 59% (hazard ratio 0.413). Zoledronic acid also increased the 1-year survival rate compared with placebo (36.3 +/- 11.2 vs. 0%, respectively). Zoledronic acid was generally well tolerated in our patient population.

CONCLUSIONS: Zoledronic acid therapy decreased the incidence of SREs and improved the 1-year survival rate of patients with bone metastases from bladder cancer, potentially through its anticancer activity.

saied zaghloul, H., "Postmortem diagnosis of early Myocardial infarction: Immunohistochemical study", the Annual Scientific Conference of Faculty of Medicine Cairo University, March,1999.
Zaghloul, N., A. Mahmoud, N. Elkasabgy, and N. Elhoffy, "PLGA-modified Syloid®-based microparticles for the ocular delivery of terconazole: In-vitro and in-vivo investigations", Drug Delivery, vol. 29, pp. 2117-2129, 2022.
ZAHER, H., H. RASHEED, M. Elkomy, R. A. HEGAZY, H. E. B. A. GAWDAT, D. abd el halim, R. M. Abdel Hay, R. A. HEGAZY, and M. AM, "Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial.", J Am Acad Dermatol. , vol. 74, issue 3, pp. 499-505, 2016.
ZAHER, H., H. RASHEED, M. M. El-Komy, R. A. HEGAZY, H. I. GAWDAT, D. A. M. Halim, R. A. M. Hay, R. A. HEGAZY, and A. M. Mohy, "Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial", Journal of the American Academy of Dermatology, vol. 74, issue 3: Mosby, pp. 499-505., 2016. Abstract

n/a

ZAHER, H., H. RASHEED, S. Esmat, R. A. HEGAZY, H. I. GAWDAT, R. A. HEGAZY, M. El-Komy, and D. M. ABDELHALIM, "Propranolol and infantile hemangiomas: Different routes of administration, a randomized clinical trial", European Journal of Dermatology, vol. 23, issue 5, no. 1, pp. 646-52, 2013. Abstract

n/a

ZAHER, H., H. RASHEED, M. M. El-Komy, R. A. HEGAZY, H. I. GAWDAT, D. M. ABDELHALIM, R. M. Abdel Hay, R. A. HEGAZY, and A. M. Mohy, "Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial.", Journal of the American Academy of Dermatology, vol. 74, issue 3, pp. 499-505, 2016 Mar. Abstract

BACKGROUND: Renin-angiotensin system components have been demonstrated in the biology of infantile hemangioma (IH). Captopril, an angiotensin-converting enzyme inhibitor, is proposed as a therapeutic alternative to oral propranolol.

OBJECTIVES: We sought to compare the benefit of propranolol and captopril in the treatment of IH, and to assess angiotensin-converting enzyme gene polymorphism in patients with IH and in control subjects.

METHODS: Thirty patients with IH and 35 healthy control subjects were enrolled in this study. Patients were randomly assigned to treatment with either propranolol or captopril. Assessment was done clinically and by measurement of serum vascular endothelial growth factor and angiotensin II in patients and control subjects. Angiotensin-converting enzyme gene polymorphism was also studied.

RESULTS: Clinical improvement was significantly better and faster in the patients treated with propranolol. Both groups showed reduced vascular endothelial growth factor and angiotensin II levels posttreatment, with a significantly higher percentage reduction in the propranolol-treated group. Cardiac side effects were reported only in the captopril-treated group. Baseline vascular endothelial growth factor level was significantly higher, and baseline angiotensin II level was significantly lower, in patients than control subjects.

LIMITATIONS: We studied a relatively small number of patients and control subjects.

CONCLUSION: Propranolol shows greater benefit than captopril in the treatment of IH.

Tourism